According to the World Health Organization, depression affects 350 million individuals, 16 million people in the United States only. Depression costs $210 billion a year in lost productivity and care for the illnesses related to the disease. However, antidepressant drugs have negative side effects and they are ineffective in 30% of the cases.

Repetitive Transcranial Magnetic Stimulation (rTMS) is an FDA approved non-invasive method for depression therapy. It consists in the administration of short electromagnetic pulses on patient’s scalp to stimulate regions of the brain involved in mood control.

Neuroprex will deliver a new rTMS system that will improve outcomes of depression treatment by stimulating deeper brain cells. It will also reduce the incidence of pain and discomfort associated with current rTMS therapy. The new device will allow a broad distribution of rTMS based therapy for both professional clinicians and, in the future, home-care settings. It will avoid reliance on drugs to people affected by depression and it will reduce the impact of depression on society.